Beyond LDL Cholesterol, a New Role for PCSK9

被引：50
|
作者：
Akram, Omar N. [1 ,2 ]
Bernier, Adeline [1 ,3 ]
Petrides, Francine [1 ]
Wong, Gida [1 ,4 ]
Lambert, Gilles [1 ,5 ]
机构：
[1] Heart Res Inst, Lipid Res Grp, Sydney, NSW, Australia
[2] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia
[3] Ecole Normale Super, F-75231 Paris, France
[4] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China
[5] Univ Nantes, Fac Med, Nantes, France
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2010年 / 30卷 / 07期
关键词：
atherosclerosis; lipoproteins; metabolism; DENSITY-LIPOPROTEIN-RECEPTOR; DOMINANT HYPERCHOLESTEROLEMIA; PLASMA-CHOLESTEROL; NONHUMAN-PRIMATES; MICE; PROPROTEIN-CONVERTASE-SUBTILISIN-KEXIN-TYPE-9;
D O I：
10.1161/ATVBAHA.110.209007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1279 / 1281
页数：3
相关论文
共 50 条
  • [21] Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Dijk, Wieneke
    Le May, Cedric
    Cariou, Bertrand
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2018, 29 (06): : 420 - 434
  • [22] New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol
    Meng, Fan-Hua
    Liu, Shuai
    Xiao, Jian
    Zhou, Yu-Xia
    Dong, Le-Wei
    Li, Yun-Feng
    Zhang, Yan-Qing
    Li, Wei-Hui
    Wang, Ju-Qiong
    Wang, Yan
    Song, Bao-Liang
    Ma, Yi-Tong
    Fu, Zhen-Yan
    Luo, Jie
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43 (07) : 1219 - 1233
  • [23] Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1
    Shiori Sato
    Yumiko Akamine
    Hideaki Kagaya
    Mitsuru Saito
    Takamitsu Inoue
    Kazuyuki Numakura
    Tomonori Habuchi
    Shigeru Satoh
    Masatomo Miura
    Pharmacological Reports, 2020, 72 : 622 - 630
  • [24] Role of PCSK9 beyond liver involvement
    Cariou, Bertrand
    Si-Tayeb, Karim
    Le May, Cedric
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (03) : 155 - 161
  • [25] Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1
    Sato, Shiori
    Akamine, Yumiko
    Kagaya, Hideaki
    Saito, Mitsuru
    Inoue, Takamitsu
    Numakura, Kazuyuki
    Habuchi, Tomonori
    Satoh, Shigeru
    Miura, Masatomo
    PHARMACOLOGICAL REPORTS, 2020, 72 (03) : 622 - 630
  • [26] Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol
    Newman, Connie B.
    Tobert, Jonathan A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : 784 - 790
  • [27] PCSK9 MUTATIONS AND LDL-CHOLESTEROL IN THE BOGALUSA HEART STUDY
    Hallman, D. M.
    Srinivasan, S.
    Chen, W.
    Boerwinkle, E.
    Berenson, G.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [28] The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol
    Dutka, Mieczyslaw
    Zimmer, Karolina
    Cwiertnia, Michal
    Ilczak, Tomasz
    Bobinski, Rafal
    HEART FAILURE REVIEWS, 2024, 29 (05) : 917 - 937
  • [29] Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality
    Benn, Marianne
    Tybjaerg-Hansen, Anne
    Nordestgaard, Borge G.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (24) : 3102 - 3114
  • [30] Common inactivating mutations in PCSK9 cause low LDL cholesterol
    Brunham, LR
    CLINICAL GENETICS, 2005, 67 (06) : 476 - 477
12345